Adding daratumumab to lenalidomide in maintenance therapy for multiple myeloma significantly reduced rates of minimal ...
Following the FDA's green light for a combo regimen of Sanofi’s Sarclisa in patients with newly diagnosed multiple myeloma ...
The application is for the treatment, called darzalex faspro, to be used in combination with an existing multiple myeloma treatment -- called bortezomib, lenalidomide and dexamethasone -- for adult ...
2d
Johnson & Johnson (JNJ) announced results from the Phase 3 CEPHEUS study demonstrating a significant clinical improvement with ...
The trial is seen as a complement to the MAIA trial, which had shown a significant overall survival benefit with daratumumab ...
Belantamab plus VRd led to promising outcomes in newly diagnosed transplant-eligible myeloma, study results showed.
The FDA has approved Sarclisa (isatuximab) in combination with bortezomib, lenalidomide, and dexamethasone for transplant-ineligible, newly diagnosed multiple myeloma.
Johnson & Johnson (NYSE:JNJ) has submitted a supplemental Biologics License Application for its drug Darzalex Faspro in ...
Despite being open for over a year across 18 countries, the trial managed to recruit only 10% of its target population.
Inc (NASDAQ:TSVT) and its partner Bristol Myers Squibb & Co (NYSE:BMY), will discontinue enrollment in its ongoing Phase 3 ...
Saad Z. Usmani, MD, MBA, FACP, FASCO, discusses the phase 3 CEPHEUS trial of daratumumab with bortezomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma.
Results for the company's Cepheus phase 3 trial showed a 60.9% improvement in eliminating cancer cells and a 43% reduction in the cancer progressing or causing death when its treatmentis used in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback